<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the management and prognosis of systemic lupus erythematosus in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the management and prognosis of systemic lupus erythematosus in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the management and prognosis of systemic lupus erythematosus in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Wallace, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Pisetsky, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter H Schur, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William FC Rigby, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic lupus erythematosus (SLE) is a chronic, occasionally life-threatening, multisystem immune-mediated disorder. Patients may present with a wide array of symptoms, signs, and laboratory findings and have a variable prognosis that depends upon the disease severity and type of organ involvement. Establishing the diagnosis of SLE may be challenging, and the approach to the diagnosis and differential diagnosis of SLE is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"
         </a>
         .)
        </p>
        <p>
         Due to the variable disease course, effective management of SLE requires regular clinical and laboratory monitoring to assess disease activity, to guide therapy to alleviate symptoms and reduce progressive organ damage, to prevent and treat relapses, to assess side effects related to drug therapy, to encourage adherence with medications, and to coordinate care with the patient's other providers.
        </p>
        <p>
         This topic will review the general issues related to the management of patients with SLE. The treatment of specific organ involvement is discussed in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">
          "Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">
          "Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4673.html" rel="external">
          "Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3092.html" rel="external">
          "Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">
          "Lupus nephritis: Therapy of lupus membranous nephropathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3066.html" rel="external">
          "Kidney transplantation in adults: Issues related to lupus nephritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4672.html" rel="external">
          "Gastrointestinal manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">
          "Non-coronary cardiac manifestations of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">
          "Coronary artery disease in systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">
          "Hematologic manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4665.html" rel="external">
          "Manifestations of systemic lupus erythematosus affecting the peripheral nervous system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H156885959">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H3430212462">
         <span class="h2">
          Goals and overview of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of therapy for patients with systemic lupus erythematosus (SLE) are to achieve remission or low disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Treatment of SLE is individualized based upon patient preferences [
         <a href="#rid3">
          3
         </a>
         ], clinical manifestations, disease activity and severity, and comorbidities. Patients require monitoring at regular intervals by a rheumatologist or other provider to optimize both nonpharmacologic and pharmacologic therapies and achieve treatment goals. Patients often have multiorgan system involvement and may require multidisciplinary care, including involvement of nephrology, dermatology, and hematology.
        </p>
        <p>
         Our management strategy for SLE is generally consistent with guidelines developed by professional organizations, including the European Alliance of Associations for Rheumatology (EULAR; formerly European League Against Rheumatism) [
         <a href="#rid2">
          2,4
         </a>
         ], the British Society for Rheumatology [
         <a href="#rid5">
          5,6
         </a>
         ], and others [
         <a href="#rid7">
          7
         </a>
         ]. Specific guidelines for the management of lupus nephritis are discussed separately in the relevant topics.
        </p>
        <p class="headingAnchor" id="H1973709025">
         <span class="h2">
          Definitions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flare
         </strong>
         – The clinical course of SLE is variable and may be characterized by unpredictable disease flares and remissions. There is no consensus on what constitutes a disease flare, but most clinicians agree that a flare refers to a measurable increase in disease activity that is clinically meaningful enough to result in a change in therapy [
         <a href="#rid8">
          8-10
         </a>
         ]. Flares are generally categorized by severity, with moderate or severe flares being the most clinically significant. A challenge in clinical practice is to stratify patients at risk for disease flares. We typically use various laboratory tests to help assess disease activity in the context of the clinical presentation and organ domain involvement to evaluate for a disease flare. (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Remission
         </strong>
         – There has been a lack of consensus on a definition of remission, despite it being a goal of therapy. Complete remission has been described as the absence of physical and laboratory abnormalities associated with SLE without the use glucocorticoids or immunosuppressive therapy, but is rarely achieved [
         <a href="#rid11">
          11-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Definitions of Remission in SLE (DORIS) Task Force proposed a definition of remission that is based on the absence of clinical disease activity as measured by the clinical Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K) = 0 and physician global assessment (PGA) &lt;0.5. The patient may be on antimalarials, low-dose glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≤5mg/day), and/or maintenance doses of immunosuppressive therapies [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low disease activity
         </strong>
         – Various concepts of low disease activity states have been proposed, including the Lupus Low Disease Activity State (LLDAS) [
         <a href="#rid16">
          16-18
         </a>
         ]. The LLDAS accepts a SLEDAI-2K ≤4 with no activity from major organ systems, no new clinical activity compared with the previous assessment, a PGA of ≤1,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose ≤7.5 mg/day and maintenance doses of antimalarials and immunosuppressive therapies [
         <a href="#rid18">
          18
         </a>
         ]. Active serology (anti-double-stranded deoxyribonucleic acid [dsDNA] and complement C3/C4) counts toward disease activity in the LLDAS definition. The various definitions of low disease activity states are associated with comparable rates of remission in terms of halting damage accrual and prevention of flares [
         <a href="#rid19">
          19-23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Definitions for complete remission or response for lupus nephritis are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Definitions of response'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H213086784">
         <span class="h1">
          ASSESSMENT OF DISEASE ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the heterogeneity of disease presentation and clinical course among patients with systemic lupus erythematosus (SLE), an assessment of disease activity should be performed at each clinic visit. Features attributable to active SLE must be distinguished from chronic damage, drug toxicities, and other conditions such as infection or fibromyalgia (or chronic centralized pain). As an example, marked proteinuria and a reduced glomerular filtration rate may result from either active inflammation or scarred glomeruli. Differentiating between these two possibilities has significant therapeutic implications, since immunosuppressive therapy should not be escalated in the latter setting. Similarly, joint pain may be related to active synovitis for which glucocorticoids may be indicated, or it may be due to avascular necrosis which is a side effect of treatment with glucocorticoids. Diffuse joint pain must also be distinguished from pain related to fibromyalgia (or central sensitization).
        </p>
        <p class="headingAnchor" id="H3666337591">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         All organ systems must be reviewed since almost any organ can be involved in SLE. If specific symptoms are present, patients should also be asked about any potential triggers such as sun exposure, infection, or discontinuation of therapy.
        </p>
        <p>
         The physical examination should include evaluation of the skin (including scalp and mucous membranes) and lymph nodes, as well as respiratory, cardiovascular, abdominal, musculoskeletal, and neurologic systems. A more detailed discussion of all of the clinical manifestations associated with SLE is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Laboratory evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory tests are also used to help assess disease activity and monitor organ-specific complications (eg, lupus nephritis) [
         <a href="#rid24">
          24
         </a>
         ]. Since there is no single marker of disease activity, clinicians must interpret the laboratory results in the appropriate clinical context. We obtain laboratory testing to assess disease activity at least every six months and more frequently in patients with active disease. (See
         <a class="local">
          'Monitoring response to therapy'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory tests
         </strong>
         – We typically check the following laboratory tests when monitoring disease activity in all patients with SLE:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complete blood count (CBC) with differential
         </strong>
         – Leukopenia is common and may reflect active disease. Anemia and thrombocytopenia may also be observed with active disease. Cytopenias may also result from drug toxicities. (See
         <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">
          "Hematologic manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute phase reactants (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP])
         </strong>
         – Increases in acute phase reactants are commonly observed in patients with SLE, and therefore may not be as reliable for detecting disease activity as is the case with other inflammatory diseases [
         <a href="#rid25">
          25-28
         </a>
         ]. Nonetheless, an elevated ESR can be associated with increased disease activity and accrued damage [
         <a href="#rid28">
          28,29
         </a>
         ]. Similarly, elevations in CRP can also be associated with disease activity. There are conflicting data on the diagnostic value of a markedly elevated CRP in distinguishing active SLE from infection; however, an elevated CRP should raise the suspicion for infection in a patient with SLE [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Urinalysis with urinary sediment
         </strong>
         – Proteinuria or cellular casts and hematuria may be due to SLE involving the kidney. (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Spot urine protein-to-creatinine ratio
         </strong>
         – Quantification of proteinuria helps assess the severity of glomerular disease [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serum creatinine and estimated glomerular filtration rate (eGFR)
         </strong>
         – Elevations in serum creatinine may reflect lupus nephritis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-double-stranded DNA (dsDNA)
         </strong>
         – Titers of anti-dsDNA antibodies often fluctuate with disease activity, particularly in patients with active glomerulonephritis. (See
         <a class="medical medical_review" href="/z/d/html/1814.html" rel="external">
          "Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complement levels (C3 and C4)
         </strong>
         – Low C3 and C4 and/or elevated C3 and C4 activation products often indicate active disease, particularly lupus nephritis. (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         With the exception of anti-dsDNA antibodies, we do not repeatedly check antinuclear antibodies (ANAs) or other specific antibodies (eg anti-Smith [Sm], Ro/SSA, La/SSB and U1 ribonucleoprotein [RNP]). It has been noted that the ANAs of some patients increase or decrease in titer over time; however, the clinical utility of this observation remains unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation of laboratory results
         </strong>
         – The most useful laboratory tests to predict an SLE flare (particularly lupus nephritis) are the onset of an increased serum titer of anti-dsDNA antibodies and a fall in complement levels (especially CH50, C3, and C4) [
         <a href="#rid33">
          33-39
         </a>
         ]. Persistently low serum levels of complement C1q are also associated with activity of lupus nephritis [
         <a href="#rid40">
          40,41
         </a>
         ]. However, not all patients with these serologic markers have active disease, and these markers do not necessarily predict disease exacerbation or "flares" [
         <a href="#rid38">
          38
         </a>
         ]. In one study, for example, 12 percent of patients with hypocomplementemia and elevated anti-DNA antibody titers had no clinical evidence of active disease [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Usage of complement activation products
         </strong>
         – Cell-bound complement activation products (CB-CAPs) are under investigation to assess SLE disease activity when other serologic markers are unhelpful.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         C4d and C3d, which are generated during complement activation, are covalently bound molecules and structures in the vicinity including red blood cells (RBCs), platelets, and/or peripheral blood B/T lymphocytes. Several reports suggest that monitoring erythrocyte-bound C4d (EC4d) may be superior to following C4 and C3 antigen levels in diagnosing SLE and monitoring its clinical course [
         <a href="#rid43">
          43-45
         </a>
         ]. The presence of B lymphocyte-bound C4d (BC4d) confirms the presence of an autoimmune process, and platelet-bound C4d (PC4d) is increased in patients with antiphospholipid syndrome and in patients with thrombosis due to SLE [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Direct measurement of complement activation may be more helpful than complement levels for establishing the diagnosis of SLE and/or monitoring the clinical course of SLE patients. This situation is particularly true for patients with anti-DNA antibodies, which are associated with complement activation. C3 and C4, which are widely used as a useful measure of SLE disease activity, are both acute phase reactants. Therefore, levels of both can rise during an SLE flare even though there is complement activation. Assessing CB-CAPs in conjunction with levels of C3, C4, and anti-DNA may help determine the presence of ongoing disease activity especially if there are changes from prior values.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Direct measurement of activation fragments such as C3a, C5a, and sC5b-9 requires specific handling, which may be difficult to replicate in an office setting. However, CB-CAPs are stable, which makes these assays more appropriate for clinical use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional investigations (including longer-term studies) will be needed prior to such tests becoming routinely employed for assessing diagnosis and evaluating the response to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other tests of limited utility
         </strong>
         – Numerous other laboratory tests assessing disease activity have been reported; however, their utility is limited because they are either unconfirmed or not accessible for routine clinical care. Some of these investigational markers that have been shown to correlate with disease activity include vitamin D receptors, and urinary interleukin (IL) 6 [
         <a href="#rid43">
          43,47-51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2659489332">
         <span class="h2">
          Additional studies in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monitoring for specific SLE-related organ involvement typically requires additional studies. Depending on the organ system in question, appropriate investigations such as electrocardiogram, lung function tests, radiographs of affected areas, computed tomography (CT) scans, and renal or other organ (eg, skin) biopsies may be required to further evaluate the abnormalities detected on clinical assessment.
        </p>
        <p class="headingAnchor" id="H421929260">
         <span class="h2">
          Disease activity and damage indices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several validated indices have been developed for research purposes to measure disease activity or damage, and their incorporation into clinical practice is limited by the time needed to complete them [
         <a href="#rid52">
          52
         </a>
         ]. All of the indices use a combination of history, examination, and laboratory data.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease activity indices
         </strong>
         – The Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K) is a scoring systems for global disease activity [
         <a href="#rid53">
          53,54
         </a>
         ]. The SLEDAI-2K does not capture improving or worsening, and does not include severity within a specific organ system. However, activity categories have been defined on the basis of the score, and a score of &gt;5 is associated with a probability of initiating therapy in &gt;50 percent of cases [
         <a href="#rid55">
          55
         </a>
         ]. Other assessment scales that assess disease activity in a single organ include the British Isles Lupus Assessment Group-2004 (BILAG-2004) [
         <a href="#rid56">
          56
         </a>
         ]. While the BILAG can assess single organs, it provides information on multiple systems and can be used in a composite form.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical trials are also using combinations of indices to create composite assessment measures for determining trial outcomes. Examples include the Systemic Lupus Erythematosus Response Index (SRI), used in the pivotal
         <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">
          belimumab
         </a>
         trials; and the BILAG-based Combined Lupus Assessment (BICLA), used in a trial of epratuzumab [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Damage indices
         </strong>
         – A damage index score is a measure for chronic damage and is typically used in clinical research for its prognostic value. The Systemic Lupus International Collaborating Clinics American College of Rheumatology damage index (SLICC/ACR-DI) is an example of a tool that measures accumulated damage that has occurred since disease onset [
         <a href="#rid59">
          59,60
         </a>
         ]. Damage can reflect the effects of either disease activity or treatment. Damage scores are mainly limited for use in clinical research for prognostic purposes [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H765961806">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3805174772">
         <span class="h2">
          General measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the therapeutic approach is highly variable on an individual level, there are some general principles that apply to all patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Photoprotection
         </strong>
         – Exposure to ultraviolet (UV) light may exacerbate or induce systemic manifestations of systemic lupus erythematosus (SLE) [
         <a href="#rid62">
          62
         </a>
         ]; however, this does not occur in all patients. Approximately one-third of patients with SLE may experience a rash or reaction when exposed to sun, another third may have some form of reaction with prolonged exposure, and another third do not experience a reaction. In general, most patients should avoid exposure to direct or reflected sunlight, and other sources of UV light (eg, fluorescent and halogen lights). Sunscreens that block both UV-A and UV-B and have a sun protection factor (SPF) ≥55 are suggested. Medications that can cause photosensitivity should also be avoided in patients with SLE  (
         <a class="graphic graphic_table graphicRef62152" href="/z/d/graphic/62152.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diet and nutrition
         </strong>
         – Limited data exist concerning the effect of dietary modification in SLE. However, a conservative approach is to recommend a balanced diet consisting of carbohydrates, proteins, and fats. Additional considerations regarding diet and nutrition in patients with SLE include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vitamins are rarely needed when patients eat a balanced diet. However, a daily multivitamin should be taken by patients who are not able to obtain an adequate diet.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The majority of patients with SLE have low serum levels of 25-hydroxyvitamin D (calcidiol) [
         <a href="#rid63">
          63
         </a>
         ], probably due, at least in part, to avoidance of sun exposure and/or use of sunscreen products. Vitamin D levels should be monitored periodically and patients with low vitamin D levels should be treated with supplemental vitamin D. (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with hypertension and/or nephritis, dietary measures such as salt restriction may be required. (See
         <a class="medical medical_review" href="/z/d/html/3877.html" rel="external">
          "Salt intake and hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3878.html" rel="external">
          "Diet in the treatment and prevention of hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exercise
         </strong>
         – Inactivity produced by acute illness causes a rapid loss of muscle mass, bone demineralization, and loss of stamina resulting in a sense of fatigue. This can usually be managed with isometric and graded exercise [
         <a href="#rid64">
          64,65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120020.html" rel="external">
          "Exercise prescription and guidance for adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking cessation
         </strong>
         – Patients should be counseled against cigarette smoking, since it has been associated with more active disease [
         <a href="#rid66">
          66,67
         </a>
         ]. Smoking adds to the baseline increased risk of accelerated atherosclerosis with coronary heart disease in those with SLE [
         <a href="#rid68">
          68,69
         </a>
         ]. There is also evidence to suggest that smoking diminishes the efficacy of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunizations
         </strong>
         – We advise that patients should receive appropriate immunizations prior to the institution of immunosuppressive therapies. Recommendations for vaccination of patients with systemic rheumatic diseases receiving immunosuppressive medications are summarized in the following table  (
         <a class="graphic graphic_table graphicRef119665" href="/z/d/graphic/119665.html" rel="external">
          table 2
         </a>
         ). Appropriate immunizations should also include coronavirus disease 2019 (COVID-19) vaccination. Additional considerations regarding the vaccine and timing of the administration for patients on selected immunosuppressive therapies is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">
          "COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 vaccination while on immunosuppressive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The influenza vaccine and pneumococcal vaccines are safe, but resultant antibody titers are somewhat less in patients with SLE than in controls [
         <a href="#rid72">
          72-74
         </a>
         ]. The quadrivalent human papilloma virus (HPV) vaccine has also been shown to be safe and reasonably effective in patients with stable SLE, without increasing disease activity or flares [
         <a href="#rid75">
          75
         </a>
         ]. The hepatitis B vaccine also appears to be safe in patients with stable SLE [
         <a href="#rid76">
          76
         </a>
         ]. Use of glucocorticoids, such as
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , or other immunosuppressive agents may contribute to the blunted antibody response. (See
         <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">
          "Glucocorticoid effects on the immune system", section on 'Impact on vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H509844069">
         <span class="h2">
          Approach to drug therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of drug therapy for SLE is highly individualized and depends on the predominant symptoms, organ involvement, response to previous therapy, and disease activity and severity. Adverse effects of individual therapeutic agents and patient preferences must also be taken into consideration when determining therapy. Family planning is also important to take into account when making treatment decisions. (See
         <a class="medical medical_review" href="/z/d/html/95507.html" rel="external">
          "Approach to contraception in women with systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3796303197">
         <span class="h3">
          Hydroxychloroquine for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with SLE with any degree and type of disease activity, we recommend treatment with
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         . Hydroxychloroquine is available as a 200 mg tablet. Patients who weigh more than 80 kg can receive the standard daily dose of 400 mg daily. However, for patients who weigh less than 80 kg, the dose must be adjusted for a maximum daily dose of 5 mg/kg/day of actual body weight. Dosing may be once daily if tolerated. Additional information regarding the dosing of hydroxychloroquine is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Administration, dosing, and monitoring'
         </a>
         .)
        </p>
        <p>
         Data from observational studies and small randomized trials support that the benefits of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         in SLE are broad. Hydroxychloroquine has been shown to have a positive impact on patient survival [
         <a href="#rid77">
          77-80
         </a>
         ]. In a meta-analysis of 21 studies, hydroxychloroquine was associated with a reduction in overall mortality (pooled hazard ratio [HR] 0.46, 95% CI 0.38-0.57), even among patients with a history of lupus nephritis (HR 0.37, 95% CI 0.25-0.54) [
         <a href="#rid81">
          81
         </a>
         ]. In addition, evidence from two small randomized trials and observational studies suggest that hydroxychloroquine reduces flare rates [
         <a href="#rid82">
          82-85
         </a>
         ]. In a study of 55 patients with clinically stable SLE who were all on hydroxychloroquine, patients who were randomly assigned to receive placebo rather than continuing on hydroxychloroquine were more likely to experience a disease flare during the six-month follow-up period (73 versus 35 percent; HR 2.5, 95% CI 1.08-5.08) [
         <a href="#rid83">
          83
         </a>
         ]. Hydroxychloroquine also reduces constitutional symptoms, musculoskeletal manifestations, and mucocutaneous manifestations [
         <a href="#rid82">
          82,86,87
         </a>
         ]. Other potential benefits of hydroxychloroquine include a reduction in thrombotic events, organ damage accrual, and cancer [
         <a href="#rid77">
          77,82,88-94
         </a>
         ].
        </p>
        <p>
         Antimalarials are generally well tolerated and serious side effects are rare. However, the risk of vision-threatening toxic retinopathy remains a major concern but can be avoided when using the appropriate doses along with routine ocular monitoring.
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         has also been associated with QTc interval prolongation, particularly in patients taking other QT-prolonging medications  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 3
         </a>
         ). Additional information regarding the potential adverse effects of hydroxychloroquine is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Monitoring for toxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         Laboratory tests to check levels of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         and its metabolites are available, and there has been an interest in testing to identify patients who are nonadherent. However, practice varies, and the role of blood level testing is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease"
         </a>
         .)
        </p>
        <p>
         Additional therapy varies from patient to patient and based upon the severity of disease and the major organ system involvement.
        </p>
        <p class="headingAnchor" id="H2951422453">
         <span class="h3">
          Escalation of therapy based on disease activity and severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the use of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , the need for additional therapy is generally guided by the predominant symptoms and organ involvement as well as the disease severity. While there is no single approach, we present examples below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild disease
         </strong>
         – Patients with mild disease may have predominantly skin (eg, a malar rash) and joint (eg, arthralgias or arthritis) involvement and may also feel increasingly fatigued. Laboratory evaluation to assess for disease activity may be unremarkable or reveal a mild leukopenia. Other than initiating treatment with
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         (if the patient is not already taking it), such patients may require no additional therapy. Alternatively, the patient may require short-term use of nonsteroidal antiinflammatory drugs (NSAIDs) or
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         7.5 mg daily (or equivalent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management of cutaneous and joint involvement of SLE are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4673.html" rel="external">
          "Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate disease
         </strong>
         – Patients with moderate disease severity may be described as having significant but non-organ-threatening disease (eg, constitutional, cutaneous, musculoskeletal, or hematologic). Patients usually respond to
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         plus short-term therapy with 5 to 15 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent) daily. Hydroxychloroquine takes approximately three months for a clinical effect to be observed. Prednisone is usually tapered once hydroxychloroquine has taken effect. A glucocorticoid-sparing immunosuppressive agent (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">
          belimumab
         </a>
         , or
         <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">
          anifrolumab
         </a>
         ) is often required to control symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe disease
         </strong>
         – A patient with organ-threatening manifestations (eg, renal and central nervous system [CNS] involvement) generally requires an initial period of intensive immunosuppressive therapy (induction therapy) to control the disease and halt tissue injury. As an example, such a patient may develop renal insufficiency and significant proteinuria due to lupus nephritis. Laboratory evaluation may reveal a low C3, C4, elevated anti-double-stranded DNA (dsDNA) antibodies, and elevated acute phase reactants. Patients are usually treated for a short period of time with high doses of systemic glucocorticoids (eg, intravenous "pulses" of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 0.5 to 1 g/day for three days in acutely ill patients, or oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 to 2 mg/kg/day in more stable patients) used alone or in combination with other immunosuppressive agents. There is a paucity of data to support the use of intravenous "pulse" versus daily oral glucocorticoids [
         <a href="#rid95">
          95
         </a>
         ]. One of the major advantages of glucocorticoid therapy is that it rapidly reduces inflammation, thereby helping to achieve disease control. However, attempts to minimize exposure must always be made, given the long-term adverse effects. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional immunosuppressive agents are typically added as glucocorticoid-sparing therapy and may include
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and may require hospitalization. This initial therapy is subsequently followed by a longer period of less intensive, and ideally less toxic, maintenance immunosuppressive therapy to consolidate remission and prevent flares. During this phase of treatment, the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or equivalent is reduced while monitoring clinical and laboratory measures of disease activity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H929096735">
         <span class="h3">
          Treatment of specific SLE manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is limited evidenced-based literature for managing organ-specific manifestations outside of the kidney and skin. Despite this, the choice of therapy is generally guided by the predominant symptoms and organ involvement.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constitutional symptoms
         </strong>
         – Constitutional symptoms such as fatigue and fever are common among patients with SLE:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fatigue among patients with SLE is often caused by a host of possibilities not directly associated with SLE. These include depression, deconditioning, disordered sleep, fibromyalgia, and iron-deficiency anemia. Once these causes of fatigue have been excluded or addressed, fatigue in patients who do not have organ-threatening SLE involvement may be reduced by low-dose glucocorticoids and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         [
         <a href="#rid96">
          96
         </a>
         ]. There are also data to suggest that
         <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">
          belimumab
         </a>
         may have beneficial effects on fatigue [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An underlying infection may be the cause of fever in a patient with SLE, particularly among those receiving significant immunosuppressive agents. After an infection has been excluded, fever associated with SLE activity should respond to NSAIDs,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , and/or low to moderate doses of glucocorticoids. Fever that does not respond to such therapy further raises the suspicion of an infectious and/or drug-related etiology. (See
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of patients with cutaneous, musculoskeletal, kidney, gastrointestinal, pulmonary, cardiovascular, hematologic, and/or neurologic involvement is discussed separately in the following topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous involvement
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">
          "Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">
          "Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Raynaud phenomenon
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arthritis and musculoskeletal manifestations
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4673.html" rel="external">
          "Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney involvement
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3092.html" rel="external">
          "Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">
          "Lupus nephritis: Therapy of lupus membranous nephropathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3066.html" rel="external">
          "Kidney transplantation in adults: Issues related to lupus nephritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal involvement
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4672.html" rel="external">
          "Gastrointestinal manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary involvement
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac involvement
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">
          "Non-coronary cardiac manifestations of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">
          "Coronary artery disease in systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic manifestations
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">
          "Hematologic manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic and neuropsychiatric manifestations
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4665.html" rel="external">
          "Manifestations of systemic lupus erythematosus affecting the peripheral nervous system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2173907132">
         <span class="h3">
          Considerations regarding specific therapies
         </span>
        </p>
        <p class="headingAnchor" id="H372900399">
         <span class="h4">
          Anifrolumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">
          Anifrolumab
         </a>
         , a monoclonal antibody to the type I interferon (IFN) receptor, has received approval by the US Food and Drug Administration (FDA) for the treatment of patients with moderate to severe SLE (but without severe active lupus nephritis or neuropsychiatric SLE) who are receiving standard therapy. Anifrolumab blocks the activity of type I IFNs, including IFN-alpha, IFN-beta, and IFN-kappa, which are cytokines that are elevated in many patients with SLE, and mutations in these IFN-signaling pathways have been linked to disease susceptibility [
         <a href="#rid98">
          98
         </a>
         ]. Anifrolumab's role in therapy is still being defined, but there appears to be a particular benefit for patients with skin and joint involvement [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         FDA approval was based on findings from three randomized trials demonstrating that more patients had reductions in overall disease activity and glucocorticoid dose with the addition of
         <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">
          anifrolumab
         </a>
         to standard therapy compared with placebo [
         <a href="#rid100">
          100-102
         </a>
         ]. In the initial phase 3 trial including 457 patients with SLE, the primary endpoint was not met, as patients in the anifrolumab group achieved a similar SLE responder index 4 (SRI-4) response (a composite measure of improvement) at 52 weeks when compared with those receiving placebo [
         <a href="#rid102">
          102
         </a>
         ]. However, there appeared to be a trend towards benefit in other endpoints including improvement in the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA), which may be a more sensitive test for detecting clinical change, as well as a reduction in glucocorticoid dose.
        </p>
        <p>
         In a subsequent phase 3 trial with 362 patients with SLE, 47 percent of patients in the
         <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">
          anifrolumab
         </a>
         group showed improvement as measured by the BICLA compared with 31 percent in the placebo group (difference 16.3 percentage points, 95% CI 6.3-26.3) at 52 weeks [
         <a href="#rid101">
          101
         </a>
         ]. More patients in the treatment group were also able to reduce their glucocorticoid dose. Adverse effects in the anifrolumab group included herpes zoster in 7 percent and bronchitis in 12 percent [
         <a href="#rid101">
          101
         </a>
         ], but in general, it appears to have a good safety profile [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         An analysis of patients enrolled in both trials indicated that patients treated with
         <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">
          anifrolumab
         </a>
         achieved a lupus low disease activity state (LLDAS) earlier, and remained in LLDAS longer, than patients treated with placebo [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4192850608">
         <span class="h4">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , a B cell-depleting chimeric monoclonal antibody, in the treatment of patients with SLE remains uncertain [
         <a href="#rid105">
          105
         </a>
         ]. Several uncontrolled observational studies have reported efficacy of rituximab in the treatment of SLE patients with and without lupus nephritis who have failed to respond to standard treatment [
         <a href="#rid106">
          106-110
         </a>
         ]. In addition, a systematic review of SLE patients with active disease refractory to glucocorticoids and/or immunosuppressive drugs assessed the efficacy and safety of rituximab on non-renal outcomes and found short-term improvements in measures of disease activity, immunologic parameters (eg, complement levels and dsDNA), arthritis, and thrombocytopenia, as well as a glucocorticoid-sparing effect [
         <a href="#rid111">
          111
         </a>
         ]. By comparison, the EXPLORER and LUNAR trials, which were both randomized trials, found that rituximab did not provide any significant benefit compared with controls [
         <a href="#rid112">
          112,113
         </a>
         ]. However, limitations in the study design of the both the EXPLORER and LUNAR trials may have prevented a determination of benefit. In each of the trials, both comparator groups were receiving high doses of glucocorticoids in addition to immune suppression; thus, it was not possible to determine the efficacy of rituximab.
        </p>
        <p>
         The LUNAR trial and the use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in patients with lupus nephritis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Combination regimens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h4">
          Agents under investigation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other therapeutic approaches have been tried or are under investigation in SLE. These include B-cell-targeted therapy (such as atacicept), anti-interleukin (IL) 6 receptor, iberdomide (cereblon E3 ligase modulator) [
         <a href="#rid114">
          114
         </a>
         ], low-dose IL-2 [
         <a href="#rid115">
          115
         </a>
         ],
         <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">
          obinutuzumab
         </a>
         (anti-CD20 monoclonal antibody) [
         <a href="#rid116">
          116,117
         </a>
         ],
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         (anti-CD38 monoclonal antibody) [
         <a href="#rid118">
          118,119
         </a>
         ], anti-CD40 monoclonal antibody [
         <a href="#rid120">
          120
         </a>
         ], and litifilimab (blood dendritic cell antigen 2 inhibitor) [
         <a href="#rid121">
          121,122
         </a>
         ]. The use of autologous CD19 chimeric antigen receptor T (CAR T) cells has also been described in patients with refractory SLE [
         <a href="#rid123">
          123,124
         </a>
         ]. Janus kinase inhibitors including
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         [
         <a href="#rid125">
          125,126
         </a>
         ] or
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         [
         <a href="#rid127">
          127
         </a>
         ] do not appear to be effective in the management of SLE. Information concerning ongoing trials in the United States of agents for patients with SLE can be found at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4675" target="_blank">
          www.clinicaltrials.gov
         </a>
         .
        </p>
        <p class="headingAnchor" id="H639299425">
         <span class="h2">
          Monitoring response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency with which monitoring laboratory tests are performed is tailored to each patient. Factors that should be taken into account when determining the frequency of visits include the history of the patient's prior symptoms, current disease activity status, disease severity, and frequency and severity of prior disease flares. As an example, a patient with active lupus nephritis may require laboratory tests every one to two weeks to monitor and guide therapy. By contrast, another patient with previously active nephritis, but whose SLE is quiescent, may be tested every three to four months.
        </p>
        <p>
         For most patients with SLE, we favor an approach in which patients are monitored every three to four months, and therapy is adjusted if there are signs of clinical worsening of the disease. Although expert groups recommend that SLE patients with stable disease be monitored less frequently (eg, at up to six-month intervals) [
         <a href="#rid128">
          128
         </a>
         ], there is evidence that these patients benefit from closer follow-up at three- to four-month intervals [
         <a href="#rid24">
          24,129
         </a>
         ]. A study including over 500 SLE patients with mild or inactive disease found that one in four patients followed over a two-year period will have a clinically silent laboratory abnormality (eg, low complement or hematuria) that could lead to a change in management [
         <a href="#rid130">
          130
         </a>
         ]. The average length of time between visits in the aforementioned study was 3.8 months, highlighting the importance of regular patient monitoring.
        </p>
        <p>
         However, most expert groups agree with monitoring all SLE patients at significant risk for developing lupus nephritis on at least a three-month basis in an effort to detect early signs of kidney disease [
         <a href="#rid4">
          4,131
         </a>
         ]. Risk factors for developing lupus nephritis include those who have elevated levels of antibodies to dsDNA [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2383738657">
         <span class="h2">
          Other treatment considerations
         </span>
        </p>
        <p class="headingAnchor" id="H1236661570">
         <span class="h3">
          Treatment of comorbid conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accelerated atherosclerosis, pulmonary hypertension, and antiphospholipid syndrome, Raynaud phenomenon, Sjögren's disease, as well as osteopenia or osteoporosis, are among the comorbid conditions which can be treated and for which screening tests are appropriately used. These comorbid disorders, for which patients with SLE have an increased risk, include [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Accelerated atherosclerosis
         </strong>
         – Modifiable risk factors for coronary heart disease can be addressed using guidelines for the general population such as smoking cessation, weight loss through dietary modification and exercise, use of statins, and optimal blood pressure control. (See
         <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">
          "Coronary artery disease in systemic lupus erythematosus", section on 'Prevention and treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         – If pulmonary hypertension is documented, management is similar to the patient with idiopathic pulmonary hypertension. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiphospholipid syndrome
         </strong>
         – The indications for therapy and specific management issues are the same in patients with antiphospholipid syndrome with or without concurrent SLE. (See
         <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">
          "Management of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Raynaud phenomenon
         </strong>
         – The management of Raynaud phenomenon is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sjögren's disease
         </strong>
         – Sjögren's disease may occur in association with SLE. The management of Sjögren's disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">
          "Overview of the management and prognosis of Sjögren's disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteopenia or osteoporosis
         </strong>
         – Osteoporosis or osteopenia is a significant problem in patients with SLE, particularly in patients receiving therapy with glucocorticoids. The treatment of this condition is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4673.html" rel="external">
          "Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibromyalgia
         </strong>
         – Fibromyalgia can affect approximately 30 percent of patients with SLE. The treatment of fibromyalgia discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5627.html" rel="external">
          "Treatment of fibromyalgia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118590.html" rel="external">
          "Overview of chronic widespread (centralized) pain in the rheumatic diseases", section on 'Systemic lupus erythematosus and Sjögren's disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H201146698">
         <span class="h3">
          Issues with specific therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergies
         </strong>
         – Allergies to antibiotics are more common among patients with SLE, with up to 30 percent of patients having an allergy to sulfonamide-containing antibiotics that include sulfamethoxazole (in
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [TMP-SMX]) and other less commonly used sulfonylarylamine antimicrobials  (
         <a class="graphic graphic_table graphicRef82011" href="/z/d/graphic/82011.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid133">
          133-135
         </a>
         ]. The most common allergic reaction is skin rash [
         <a href="#rid133">
          133
         </a>
         ]. Sulfonamide-containing antimicrobials have also been associated with SLE exacerbations and should therefore be avoided, if possible [
         <a href="#rid133">
          133,136
         </a>
         ]. In the general population, nonantimicrobial drugs that contain a nonarylamine sulfonamide (eg, diuretics, sulfonylurea hypoglycemics, a few NSAIDs)  (
         <a class="graphic graphic_table graphicRef57629" href="/z/d/graphic/57629.html" rel="external">
          table 5
         </a>
         ) are generally not cross-reactive with sulfonamide antimicrobial hypersensitivity and, in the author's experience, are far less likely to be associated with exacerbations of SLE. (See
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients", section on 'Nonantimicrobial sulfonamides'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug-induced lupus
         </strong>
         – By contrast, medications that cause drug-induced lupus, such as
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         , do not cause exacerbations of idiopathic SLE. This observation is a presumed reflection of the pathogenetic differences between the two disorders. However, while we use most other agents that may cause drug-induced lupus, we avoid the use of
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         in patients with established (idiopathic) SLE. (See
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – Unresponsiveness to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is poorly studied and not well documented in the literature, but has been observed and described by clinicians, and may affect patients with SLE [
         <a href="#rid137">
          137
         </a>
         ]. Estimates as high as approximately 15 percent of the general population may not adequately convert prednisone to its active metabolite. Patients with liver disease are also thought to be impacted by this problem. Thus, some clinicians favor using
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         rather than prednisone in patients with SLE who are suspected to have liver disease. A limited or poor response to prednisone should also prompt consideration of a switch to an equivalent dose of methylprednisolone. In addition, methylprednisolone is generally preferred over prednisone for pediatric patients with SLE whose liver is presumed to be immature.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation therapy
         </strong>
         – Radiation therapy for the treatment of malignancy should not be withheld or avoided in patients with SLE. In the past, several case reports of increased toxicity following therapeutic radiation in patients with systemic rheumatic diseases made radiation oncologists wary of treating patients with SLE [
         <a href="#rid138">
          138-141
         </a>
         ]. However, additional observational data have also suggested that radiation therapy in patients with SLE is not associated with an increased risk of toxicity [
         <a href="#rid142">
          142-145
         </a>
         ]. An exception might be patients with SLE who also have overlapping features of systemic sclerosis (SSc) may be at increased risk of induction of pulmonary fibrosis, and treatment decisions should be made on an individual basis with careful consideration of the potential risks and benefits of therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H941655499">
         <span class="h3">
          Pregnancy and contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy should be avoided during active disease (especially with significant organ impairment) due to the high risk of miscarriage and exacerbation of SLE. Women with SLE should be counseled not to become pregnant until the disease has been quiescent for at least six months. A detailed discussion on pregnancy in patients with SLE is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">
          "Pregnancy in women with systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p>
         Issues related to contraception in patients with SLE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/95507.html" rel="external">
          "Approach to contraception in women with systemic lupus erythematosus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2005318118">
         <span class="h3">
          Assessment of adherence to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonadherence to medications appears to be relatively common among patients with SLE [
         <a href="#rid146">
          146
         </a>
         ]. In some cases, suspected treatment resistance can be related to nonadherence rather than actual resistance to immunosuppressive therapy. An approach assessing adherence among patients with SLE is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3092.html" rel="external">
          "Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy", section on 'Assessment of patient adherence to therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic lupus erythematosus (SLE) can run a varied clinical course, ranging from a relatively benign illness to a rapidly progressive disease with fulminant organ failure and death.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality rates
         </strong>
         – The five-year survival rate in SLE has dramatically increased since the mid-20
         <sup>
          th
         </sup>
         century, from approximately 40 percent in the 1950s to greater than 90 percent since the 1980s [
         <a href="#rid147">
          147-151
         </a>
         ]. The improvement in patient survival is probably due to multiple factors including increased disease recognition with more sensitive diagnostic tests [
         <a href="#rid152">
          152
         </a>
         ], earlier diagnosis or treatment, the inclusion of milder cases, increasingly judicious therapy, and prompt treatment of complications [
         <a href="#rid153">
          153
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite these improvements, patients with SLE still have mortality rates ranging from two to five times higher than that of the general population [
         <a href="#rid154">
          154,155
         </a>
         ]. Based on mortality data from the United States Centers for Disease Control and Prevention (CDC) from 2000 to 2015, SLE ranked among the top 20 leading causes of death in females between the ages of 5 and 64 [
         <a href="#rid156">
          156
         </a>
         ]. In another large population-based study in the United States, mortality risk from SLE was higher among women, African Americans, and residents of the South [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes of death
         </strong>
         – The major causes of death in the first few years of illness are active disease (eg, central nervous system [CNS] and kidney disease) or infection due to immunosuppression. Achieving remission or a low disease activity state is associated with a reduced risk of death [
         <a href="#rid158">
          158
         </a>
         ]. Causes of late death include cardiovascular disease, complications of SLE (eg, end-stage kidney disease), and treatment complications [
         <a href="#rid153">
          153,159-165
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prognostic factors associated with increased mortality in SLE include [
         <a href="#rid148">
          148,149,161,166-173
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney disease (especially diffuse proliferative glomerulonephritis)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Male sex
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Young age
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Older age at presentation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low socioeconomic status
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Being a Black person
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of antiphospholipid antibodies
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antiphospholipid antibody syndrome
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High overall disease activity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency of the different causes of death is best illustrated by a 2014 meta-analysis of 12 studies that included 27,123 patients with SLE (4993 observed deaths) [
         <a href="#rid174">
          174
         </a>
         ]. This analysis reported an overall threefold increased risk of death in patients with SLE (standardized mortality rate [SMR] 2.98, 95% CI 2.32-3.83) when compared with the general population. The risks of death due to cardiovascular disease, infection, and kidney disease were significantly increased. Mortality due to malignancy was not found to be increased, while patients with kidney disease were found to have the highest mortality risk (SMR 7.90, 95% CI 5.5-11.0).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morbidity
         </strong>
         – Despite a reduction in the risk of premature death, patients with SLE are at risk for significant morbidity due both to active disease and to the side effects of drugs such as glucocorticoids and cytotoxic agents [
         <a href="#rid175">
          175
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Factors that may be associated with a shorter delay between disease onset and organ damage include [
         <a href="#rid176">
          176,177
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Being an Asian or Hispanic person
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Greater disease activity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A history of thrombotic events
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glucocorticoid use of less than 10 mg per day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid effects
         </strong>
         – Glucocorticoid use at doses equivalent to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≥10 mg/day has been associated with a longer time from SLE onset to organ damage, but as noted above, long-term use of higher doses of glucocorticoids has significant risks that must be considered. However, the relationship between glucocorticoid dose and organ damage is not well defined, and there are conflicting results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A cohort of 525 patients with SLE from a single academic medical center was followed for up to 10 years on varying doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and the findings suggested that low doses of prednisone do not result in a substantially increased risk of irreversible organ damage [
         <a href="#rid178">
          178
         </a>
         ]. However, glucocorticoid-induced avascular necrosis of the hips and knees, osteoporosis, fatigue, and cognitive dysfunction have become particularly important problems as patients live longer with their illness with a concomitant increase in total glucocorticoid exposure [
         <a href="#rid179">
          179
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospitalization
         </strong>
         – Patients with SLE experience high rates of hospital admission and readmission. In the United States, more than half of Medicare SLE hospitalizations occur in patients younger than 65, who qualify for Medicare due to chronic disability or end-stage kidney disease [
         <a href="#rid180">
          180
         </a>
         ]. In a study of 10,866 Medicare hospitalizations among patients with SLE, the 30-day rehospitalization rate was highest among young adults (aged 18 to 36 years old) [
         <a href="#rid181">
          181
         </a>
         ]. The rehospitalization rate for young adults with SLE was higher than the rehospitalization rate for young adults with other diagnoses (36 versus 26 percent). Predictors of rehospitalization for all Medicare patients with SLE included coagulopathy, congestive heart failure, illicit drug use, fluid and electrolyte disorders, and paralysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study of 132,400 hospitalized adults with SLE, 14.3 percent were readmitted within 30 days of discharge [
         <a href="#rid182">
          182
         </a>
         ]. The factors associated with the highest odds of readmission included autoimmune hemolytic anemia (odds ratio [OR] 1.86), glomerular disease (OR 1.27), pericarditis (OR 1.35), heart failure (OR 1.34), age 18 to 30 years versus age greater than 65 years (OR 1.28), and Medicare (OR 1.20) or Medicaid (OR 1.26) insurance. Readmissions of SLE patients with Medicaid may be tied to poor access to care and sociodemographics [
         <a href="#rid183">
          183
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignancy risk
         </strong>
         – The overall risk of malignancy is increased among patients with SLE. In a study of adults who used Finland's National Health Insurance, the incidence ratio for any malignancy compared with a population without SLE was 1.4 (95% CI 1.1-1.8) [
         <a href="#rid184">
          184
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with SLE have a three- to fourfold increased risk of non-Hodgkin lymphoma compared with the general population [
         <a href="#rid185">
          185
         </a>
         ]. Non-Hodgkin lymphoma in patients with SLE often has an aggressive histologic subtype (eg, diffuse large B-cell lymphoma), which is associated with an increased risk of death [
         <a href="#rid186">
          186,187
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with SLE may also be at increased risk of cancer of the vulva, lung, thyroid, and hepatobiliary tract, although this has not been well established [
         <a href="#rid185">
          185,188-195
         </a>
         ].
        </p>
        <p>
         Although the overall risk of death due to malignancy does not appear to be increased in SLE patients, the risk of death due to specific malignancies is significantly increased among SLE patients when compared with the general population [
         <a href="#rid163">
          163,184,185,188-195
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Likelihood of clinical remission
         </strong>
         – After appropriate therapy, remission of at least one-year duration is achieved by 7 to 25 percent of patients with SLE [
         <a href="#rid12">
          12,196
         </a>
         ]. However, only 2 to 7 percent of patients will achieve remission lasting for five years or longer [
         <a href="#rid11">
          11,12
         </a>
         ]. Half of patients who relapse after achieving remission will not achieve a subsequent remission [
         <a href="#rid196">
          196
         </a>
         ]. Predictors of a sustained (ie, longer than three years) drug-free remission include [
         <a href="#rid11">
          11,12,16,196-198
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Being a White person (adjusted hazard ratio [HR] 2.16)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &gt;32 at diagnosis (adjusted HR 1.92)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of kidney involvement (adjusted HR 2.55)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of antiphospholipid antibody syndrome (adjusted HR 4.92)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Definitions for clinical remission are discussed separately. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4236485371">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110740.html" rel="external">
          "Society guideline links: Systemic lupus erythematosus"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119580.html" rel="external">
          "Society guideline links: Cutaneous lupus erythematosus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15480.html" rel="external">
          "Patient education: Lupus (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/581.html" rel="external">
          "Patient education: Systemic lupus erythematosus (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/582.html" rel="external">
          "Patient education: Systemic lupus erythematosus and pregnancy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11414608">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals and overview of therapy
         </strong>
         – The goals of therapy for systemic lupus erythematosus (SLE) patients are to achieve remission or low disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life. Treatment of SLE is individualized based upon patient preferences, clinical manifestations, disease activity and severity, and comorbidities (See
         <a class="local">
          'Goals and overview of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of disease activity
         </strong>
         – Given the heterogeneity of disease presentation and clinical course among patients with SLE, an assessment of disease activity should be performed at each clinic visit. In clinical practice, disease activity and severity are assessed using a combination of clinical history, physical examination, laboratory and imaging studies for specific organs, and serologic tests. (See
         <a class="local">
          'Assessment of disease activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory evaluation
         </strong>
         – We typically check the following laboratory tests when assessing disease activity in patients with SLE: complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), spot urine protein and creatinine, serum creatinine, estimated glomerular filtration rate (eGFR), anti-double-stranded DNA (dsDNA), and complement levels (C3 and C4). (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Additional studies in selected patients
         </strong>
         – Monitoring for specific SLE-related organ involvement typically requires additional studies. Depending on the organ system in question, appropriate investigations such as electrocardiogram, lung function tests, radiographs of affected areas, CT scans, and renal or other organ (eg, skin) biopsies may be required. (See
         <a class="local">
          'Additional studies in selected patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General measures
         </strong>
         – Several nonpharmacologic and preventive interventions important in the management of SLE include photoprotection, diet and nutrition, exercise, smoking cessation, and maintenance of appropriate immunizations. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hydroxychloroquine
         </strong>
         <strong>
          for all patients
         </strong>
         – Among patients with SLE with any degree and type of disease activity, we recommend administering
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ), unless a contraindication exists. (See
         <a class="local">
          'Hydroxychloroquine for all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Escalation of therapy based on disease activity and severity
         </strong>
         – Additional therapy is based upon the severity of disease and the combination of manifestations. While there is no single approach, we present examples below (see
         <a class="local">
          'Escalation of therapy based on disease activity and severity'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Mild disease
         </strong>
         – Patients with mild disease (eg, with skin, joint, and mucosal involvement) are administered
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         . Such patients may require no additional therapy. Alternatively, the patient may require short-term use of nonsteroidal antiinflammatory drugs (NSAIDs), and/or low-dose glucocorticoids (eg, ≤7.5 mg
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         equivalent per day).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Moderate disease
         </strong>
         – Patients with moderate disease may be described as having significant but non-organ-threatening disease (eg, constitutional, cutaneous, musculoskeletal, or hematologic). Patients usually respond to
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         or
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         plus short-term therapy with 5 to 15 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent) daily. Prednisone is usually tapered once hydroxychloroquine has taken effect. A glucocorticoid-sparing immunosuppressive agent (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">
          belimumab
         </a>
         , or
         <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">
          anifrolumab
         </a>
         ) is often required to control symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Severe disease
         </strong>
         – Patients with organ-threatening manifestations (eg, renal and central nervous system [CNS] involvement) generally require an initial period of intensive immunosuppressive therapy (induction therapy) to control the disease and halt tissue injury. Patients are usually treated for a short period of time with high doses of systemic glucocorticoids (eg, 1 to 2 mg/kg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or equivalent or intermittent intravenous "pulses" of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ) used alone or in combination with other immunosuppressive agents (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ). This initial therapy is subsequently followed by a longer period of less intensive and, ideally, less toxic maintenance therapy to consolidate remission and prevent flares. During this phase of treatment, the dose of prednisone or equivalent is reduced while monitoring clinical and laboratory measures of disease activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring response to therapy
         </strong>
         – The frequency with which monitoring laboratory tests are performed is tailored to each patient. However, for most patients with SLE, we favor an approach in which patients are monitored every three to four months, and therapy is adjusted if there are signs of clinical worsening of the disease. (See
         <a class="local">
          'Monitoring response to therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other treatment considerations
         </strong>
         – Other important treatment considerations include treatment of comorbid conditions, issues related to specific medications (eg, with sulfonamide-containing antibiotics), and precautions around pregnancy and contraception. (See
         <a class="local">
          'Other treatment considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – SLE can run a varied clinical course, ranging from a relatively benign illness to a rapidly progressive disease with fulminant organ failure and death. Clinical remission after appropriate therapy is uncommon, and, when it is achieved, it is often not sustained. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morbidity and mortality
         </strong>
         – Patients with SLE have mortality rates ranging from two to five times higher than that of the general population. The major causes of death in the first few years of illness are active disease (eg, CNS and kidney) or infection due to immunosuppression, while causes of late death include complications of SLE (eg, endstage kidney disease), treatment complications, and cardiovascular disease. Patients are also at risk for significant morbidity due to both active disease and the side effects of drugs such as glucocorticoids and cytotoxic agents. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus 2008; 17:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018; 57:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology (Oxford) 2018; 57:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 2018; 77:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a definition of disease flare in lupus. Lupus 2011; 20:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003; 42:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petri M, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009; 36:2476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015; 74:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medina-Quiñones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. Arthritis Care Res (Hoboken) 2016; 68:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiman AJ, Urowitz MB, Ibañez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014; 41:1808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tselios K, Gladman DD, Urowitz MB. How can we define low disease activity in systemic lupus erythematosus? Semin Arthritis Rheum 2019; 48:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polachek A, Gladman DD, Su J, Urowitz MB. Defining Low Disease Activity in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2017; 69:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford) 2017; 56:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018; 77:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tselios K, Gladman DD, Touma Z, et al. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2019; 71:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis 2017; 76:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugarte-Gil MF, Hanly J, Urowitz M, et al. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022; 81:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertoli AM, Vilá LM, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008; 35:2355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilá LM, Alarcón GS, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 2005; 32:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stojan G, Fang H, Magder L, Petri M. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus 2013; 22:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firooz N, Albert DA, Wallace DJ, et al. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 2011; 20:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birmingham DJ, Shidham G, Perna A, et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis 2014; 73:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linnik MD, Hu JZ, Heilbrunn KR, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010; 62:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esdaile JM, Abrahamowicz M, Joseph L, et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petri MA, van Vollenhoven RF, Buyon J, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65:2143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akhter E, Burlingame RW, Seaman AL, et al. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011; 20:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marto N, Bertolaccini ML, Calabuig E, et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares. J Rheumatol 1994; 21:2239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey-Goldman R, Alexander RV, Conklin J, et al. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. ACR Open Rheumatol 2021; 3:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arriens C, Alexander RV, Narain S, et al. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med 2020; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill JT, Petri MA, Buyon J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 2018; 5:e000263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein A, Alexander RV, Zack DJ. A Review of Complement Activation in SLE. Curr Rheumatol Rep 2021; 23:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis 2013; 5:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok CC, Birmingham DJ, Ho LY, et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus 2012; 21:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012; 12:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Tucci M, Narain S, et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006; 5:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009; 23:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora S, Isenberg DA, Castrejon I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care Res (Hoboken) 2020; 72 Suppl 10:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010; 19:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56:4113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014; 73:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber MRW, Johnson SR, Gladman DD, et al. Evolving concepts in systemic lupus erythematosus damage assessment. Nat Rev Rheumatol 2021; 17:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehmann P, Homey B. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev 2009; 8:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010; 19:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robb-Nicholson LC, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Br J Rheumatol 1989; 28:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tench CM, McCarthy J, McCurdie I, et al. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology (Oxford) 2003; 42:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Formica MK, Palmer JR, Rosenberg L, McAlindon TE. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol 2003; 30:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003; 30:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007; 34:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hak AE, Karlson EW, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 2009; 61:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol 2015; 72:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006; 15:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murdaca G, Orsi A, Spanò F, et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 2014; 13:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuruma KA, Borba EF, Lopes MH, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008; 17:281.
          </a>
         </li>
         <li class="breakAll">
          Wallace, DJ. Antimalarial therapies. In: Dubois' Lupus Erythematosus, 7th edition, Wallace, DJ, Hahn, BH (Eds), Williams &amp; Wilkins, Baltimore 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai T, Zhao J, Yang Y, et al. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. Lupus 2022; 31:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meinão IM, Sato EI, Andrade LE, et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida-Brasil CC, Hanly JG, Urowitz M, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022; 81:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belmont HM. Treatment of systemic lupus erythematosus - 2013 update. Bull Hosp Jt Dis (2013) 2013; 71:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fessler BJ, Alarcón GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013; 40:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pons-Estel GJ, Alarcón GS, González LA, et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res (Hoboken) 2010; 62:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:3073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li XB, Cao NW, Chu XJ, et al. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies. Ann Med 2021; 53:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007; 16:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strand V, Berry P, Lin X, et al. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res (Hoboken) 2019; 71:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192:5459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med 2018; 5:e000284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol 2017; 69:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019; 1:e208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatham WW, Furie R, Saxena A, et al. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study. Arthritis Rheumatol 2021; 73:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morand EF, Abreu G, Furie RA, et al. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis 2023; 82:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leandro M, Isenberg DA. Rituximab - The first twenty years. Lupus 2021; 30:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011; 50:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2014; 44:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill JT, Werth VP, Furie R, et al. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med 2022; 386:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2020; 79:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford) 2017; 56:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold J, Dass S, Twigg S, et al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology (Oxford) 2022; 61:4905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med 2020; 383:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roccatello D, Fenoglio R, Caniggia I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med 2023; 29:2041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayne DR, Steffgen J, Romero-Diaz J, et al. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Arthritis Rheumatol 2023; 75:1983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med 2022; 387:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ. Progress toward Better Treatment of Lupus. N Engl J Med 2022; 387:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mougiakakos D, Krönke G, Völkl S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med 2021; 385:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022; 28:2124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petri M, Bruce IN, Dorner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999; 42:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 2013; 40:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol 1992; 19:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope J, Jerome D, Fenlon D, et al. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aceves-Avila FJ, Benites-Godínez V. Drug allergies may be more frequent in systemic lupus erythematosus than in rheumatoid arthritis. J Clin Rheumatol 2008; 14:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffries M, Bruner G, Glenn S, et al. Sulpha allergy in lupus patients: a clinical perspective. Lupus 2008; 17:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen D, Rajbhandary R, Carlino A, et al. Are there patients with inflammatory disease who do not respond to prednisone? J Rheumatol 2010; 37:1559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Naeyer B, De Meerleer G, Braems S, et al. Collagen vascular diseases and radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 1999; 44:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold DG, Miller RC, Pinn ME, et al. Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. Radiother Oncol 2008; 87:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hölscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. Radiother Oncol 2006; 78:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan C, Mindrum M, Silverman C, et al. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 2003; 9:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benk V, Al-Herz A, Gladman D, et al. Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. Arthritis Rheum 2005; 53:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 1993; 71:3744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rakfal SM, Deutsch M. Radiotherapy for malignancies associated with lupus: case reports of acute and late reactions. Am J Clin Oncol 1998; 21:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehat P, Atiquzzaman M, Esdaile JM, et al. Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken) 2017; 69:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 13:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006; 85:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seleznick MJ, Fries JF. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991; 21:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004; 3:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh RR, Yen EY. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus 2018; 27:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yen EY, Singh RR. Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015. Arthritis Rheumatol 2018; 70:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yen EY, Shaheen M, Woo JMP, et al. 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. Ann Intern Med 2017; 167:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. Lancet Rheumatol 2022; 4:e822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995; 22:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björnådal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartella S, Cavazzana I, Ceribelli A, et al. Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. Autoimmunity 2013; 46:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995; 8:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995; 38:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin JR, Bombardier C, Farewell VT, et al. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994; 37:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drenkard C, Villa AR, Alarcón-Segovia D, Pérez-Vázquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh SJ, Algert C, Gregorio DI, et al. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995; 22:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadee S, Tikly M, Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46:1487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013; 43:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 2014; 66:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. Rheumatology (Oxford) 2004; 43:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toloza SM, Roseman JM, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004; 50:3177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguirre A, Izadi Z, Trupin L, et al. Race, Ethnicity, and Disparities in the Risk of End-Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. Arthritis Care Res (Hoboken) 2023; 75:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thamer M, Hernán MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009; 36:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartels CM, Chodara A, Chen Y, et al. One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days. Semin Arthritis Rheum 2021; 51:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schletzbaum M, Kind AJ, Chen Y, et al. Age-Stratified 30-day Rehospitalization and Mortality and Predictors of Rehospitalization Among Patients With Systemic Lupus Erythematosus: A Medicare Cohort Study. J Rheumatol 2023; 50:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Najjar R, Alexander SA, Hughes GC, et al. Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the United States: A Nationwide Study. Arthritis Care Res (Hoboken) 2023; 75:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pryor KP, Barbhaiya M, Costenbader KH, Feldman CH. Disparities in Lupus and Lupus Nephritis Care and Outcomes Among US Medicaid Beneficiaries. Rheum Dis Clin North Am 2021; 47:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kariniemi S, Rantalaiho V, Virta LJ, et al. Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival. Lupus 2022; 31:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayed M, Bernatsky S, Ramsey-Goldman R, et al. Lupus and cancer. Lupus 2009; 18:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernatsky S, Ramsey-Goldman R, Rajan R, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löfström B, Backlin C, Sundström C, et al. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007; 66:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 1995; 22:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nived O, Bengtsson A, Jönsen A, et al. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 2001; 10:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996; 39:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998; 46:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165:2337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013; 42:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore) 1996; 75:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durao-Carvalho G, Fernández-González R, Goulden B, et al. Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period. Rheumatology (Oxford) 2022; 62:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985; 12:916.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4675 Version 69.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24739325" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17504841" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18250130" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30926722" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29029350" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29029296" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30045853" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148601" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : International consensus for a definition of disease flare in lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12810926" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Definition and treatment of lupus flares measured by the BILAG index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19833757" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26223434" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prolonged remission in Caucasian patients with SLE: prevalence and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16078321" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prolonged remission in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26554745" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25086082" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prolonged clinical remission in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34819388" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : 2021 DORIS definition of remission in SLE: final recommendations from an international task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30415943" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : How can we define low disease activity in systemic lupus erythematosus?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27696791" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Defining Low Disease Activity in Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26458737" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27803306" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28970217" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30055090" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28939626" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35944946" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19892750" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18221991" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19004040" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175928" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265693" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23761098" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19035410" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : C-reactive protein and systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21436216" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24092416" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7231154" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11665975" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818711" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20187154" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11665976" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607885" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23754628" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813587" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286009" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7699623" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538130" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32371480" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cell-bound complement activation products associate with lupus severity in SLE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29868177" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33569681" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A Review of Complement Activation in SLE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23904865" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21993384" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22810055" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16890891" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Urinary biomarkers in lupus nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19591781" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The search for lupus biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33091256" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11838846" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Systemic lupus erythematosus disease activity index 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910390" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : SLEDAI-2K for a 30-day window.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22588757" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18050213" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23313811" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19714615" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Novel evidence-based systemic lupus erythematosus responder index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10685799" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9153540" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33859399" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Evolving concepts in systemic lupus erythematosus damage assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19167524" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Clinic and pathophysiology of photosensitivity in lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19897520" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Vitamin D insufficiency in a large female SLE cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2590802" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effects of aerobic conditioning in lupus fatigue: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12730519" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12784393" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12784392" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cigarette smoking and disease activity in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17117488" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790130" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25648824" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22105815" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Impact of smoking in cutaneous lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17153850" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778224" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Antigen-specific antibody responses in lupus patients following immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24044940" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22589375" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576737" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17080912" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18413408" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18413408" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17389655" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36325952" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19103632" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1984192" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8803897" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34911705" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24151947" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Treatment of systemic lupus erythematosus - 2013 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7983646" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880829" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23588942" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20391486" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20131232" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16200586" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11434574" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34553648" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664228" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8153401" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Antimalarial agents and lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30320964" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24907379" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Type I interferon in the pathogenesis of lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30588322" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28130918" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Anifrolumab, an Anti-Interferon-αReceptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31851795" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38229377" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33225631" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36690388" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33459161" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Rituximab - The first twenty years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17412738" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19333973" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19578100" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398661" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20506527" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24830791" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20039413" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22231479" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35294813" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31537547" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28407142" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35266512" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32937047" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37563241" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Daratumumab monotherapy for refractory lupus nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37192040" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36069871" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36069878" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Progress toward Better Treatment of Lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34347960" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36109639" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043749" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35798534" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22556106" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10513791" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23457385" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32220834" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12004788" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1629825" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Antibiotic allergy in systemic lupus erythematosus: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12610805" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Frequency of adverse drug reactions in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18679134" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Drug allergies may be more frequent in systemic lupus erythematosus than in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18372360" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Sulpha allergy in lupus patients: a clinical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20675852" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Are there patients with inflammatory disease who do not respond to prednisone?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10421528" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Collagen vascular diseases and radiation therapy: a critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18158195" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18506734" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Toxicity of radiotherapy in patients with collagen vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445999" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Influence of connective tissue diseases on the expression of radiation side effects: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14740974" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696566" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8490925" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Acute and late reactions to radiation therapy in patients with collagen vascular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9499258" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Radiotherapy for malignancies associated with lupus: case reports of acute and late reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28086003" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11604587" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Mortality and causes of death in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530779" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16721257" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Predictors of survival in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18793004" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19136143" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Understanding the epidemiology and progression of systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1749941" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Variables associated with decreased survival in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8651844" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15351310" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30016928" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : SLE mortality remains disproportionately high, despite improvements over the last decade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29671279" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29086801" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4011845" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Mortality in systemic lupus erythematosus: the bimodal pattern revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7562755" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7562756" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11959764" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16868977" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Mortality in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15088296" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23706114" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8605261" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Mortality in the rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7575699" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147934" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7932417" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14718326" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8523342" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Divergent racial trends in mortality from systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17681980" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Causes and predictors of death in South Africans with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23786872" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24106157" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15161983" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15476246" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35452566" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Race, Ethnicity, and Disparities in the Risk of End-Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208608" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Prednisone, lupus activity, and permanent organ damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10943870" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Damage in systemic lupus erythematosus and its association with corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33813261" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35970523" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Age-Stratified 30-day Rehospitalization and Mortality and Predictors of Rehospitalization Among Patients With Systemic Lupus Erythematosus: A Medicare Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35439363" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the United States: A Nationwide Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34042053" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Disparities in Lupus and Lupus Nephritis Care and Outcomes Among US Medicaid Beneficiaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36200539" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19395448" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Lupus and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16162903" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Non-Hodgkin's lymphoma in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17517757" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9125261" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7473469" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Risk of malignancy in women with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11480849" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8651970" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Malignancy in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9676054" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Increased risk of malignancy in patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880596" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : An international cohort study of cancer in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16287762" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : The risk of lymphoma development in autoimmune diseases: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23410586" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Cancer risk in systemic lupus: an updated international multi-centre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8606630" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Remission of systematic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35451471" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3878878" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Serological and clinical remission in systemic lupus erythematosus.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
